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Abstract
Background: A recurrent somatic mutation, E17K, in the pleckstrin homology domain of the
AKT1 gene, has been recently described in breast, colorectal, and ovarian cancers. AKT1 is a pivotal
mediator of signalling pathways involved in cell survival, proliferation and growth. The E17K
mutation stimulates downstream signalling and exhibits transforming activity in vitro and in vivo.
Findings: We developed a sensitive high resolution melting (HRM) assay to detect the E17K
mutation from formalin-fixed paraffin-embedded tumours. We screened 219 non-small cell lung
cancer biopsies for the mutation using HRM analysis. Four samples were identified as HRM positive.
Subsequent sequencing of those samples confirmed the E17K mutation in one of the cases. A rare
single nucleotide polymorphism was detected in each of the remaining three samples. The E17K
was found in one of the 14 squamous cell carcinomas. No mutations were found in 141
adenocarcinomas and 39 large cell carcinomas.
Conclusion: The AKT1 E17K mutation is very rare in lung cancer and might be associated with
tumorigenesis in squamous cell carcinoma. HRM represents a rapid cost-effective and robust
screening of low frequency mutations such as AKT1 mutations in clinical samples.
Findings
Genetic alterations in AKT
The human homologues of the viral oncogene v-akt,
encode serine/threonine protein kinases which have a piv-
otal activity in the PI3K-related signalling pathway, affect-
ing cell survival, proliferation and invasion [1]. The three
highly homologous isoforms, AKT1, AKT2 and AKT3 are
composed of three functional domains: an amino termi-
nal pleckstrin homology (PH) domain, a central catalytic
domain, and a carboxyl terminal regulatory domain with
the hydrophobic motif. Deregulated AKT activity is a well-
established genetic defect implicated in tumorigenesis [2].
On activation, AKT exerts its anti-apoptotic and prolifera-
tive cellular functions through its kinase activity on vari-
ous substrates [3].
Frequent genetic alterations of the AKT genes, especially
AKT2, have been demonstrated in human malignancies
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[4,5]. AKT1 amplification was initially identified in gastric
cell lines [6] and has shown to be associated with cisplatin
resistance in lung cancer cells through the mTOR pathway
[7]. No AKT1  somatic mutation was described until
Carpten et al. identified an E17K (c.49G>A) mutation in
the pleckstrin homology domain from breast, ovarian and
colorectal cancers [8]. Transforming activity was demon-
strated both in vivo and in vitro. The mutation causes con-
stitutive activation by localisation to the plasma
membrane in a PI3K-independent manner.
It is of interest which tumour types other than breast,
ovarian and colorectal cancers also show the recurrent
E17K mutation. The mutation was not found in acute
myeloid leukaemia and brain tumours [9,10]. In this
study, we used high resolution melting (HRM) analysis to
screen the AKT1 E17K mutation in a panel of 219 non-
small cell lung cancer (NSCLC) tumour biopsies to deter-
mine if this mutation may occur in NSCLC.
Methods
A total of 219 NSCLC samples were included in this study.
Two hundred of these samples had previously been tested
for EGFR and KRAS mutations. Our panel of samples have
also been described in another recent study [20]. Of those,
141 were adenocarcinomas, 39 were large cell carcinomas,
14 were squamous cell carcinomas, and 25 were of
unknown or other histology. Genomic DNA was extracted
using the DNeasy Tissue kit (Qiagen, Hilden, Germany)
following proteinase K digestion at 56°C for 3 days. This
study was approved by the Ethics of Human Research
Committee at the Peter MacCallum Cancer Centre
(project number 03/90).
HRM primers were designed to screen the E17K mutation,
generating a 78 bp product. The sequences of the primers
were 5'-CGAGGGTCTGACGGGTAGAGTG-3' (forward)
and 5'-GGCCGCCAGGTCTTGATGT-3' (reverse). PCR for
HRM analysis was performed on the Rotor-Gene 6000
(Corbett Research, Sydney, Australia) in the presence of
the fluorescent DNA intercalating dye, SYTO 9 (Invitro-
gen, Carlsbad, CA). The reaction mixture in a final volume
of 20 μl was made using HotStarTaq (Qiagen) as follows;
1 × PCR buffer, 2.5 mM MgCl2, 200 nM of each primer, 5
ng of genomic DNA, 200 μM of dNTPs, 5 μM of SYTO 9,
and 0.5 U of Taq polymerase. The cycling and melting
conditions were as follows; one cycle of 95°C for 15 min-
utes; 50 cycles of 95°C for 10 seconds, 65°C for 10 sec-
onds with an initial 10 cycles of touchdown (1°C/cycle),
72°C for 20 seconds; one cycle of 97°C for 1 minute and
a melt from 70°C to 95°C with the temperature rising
0.2°C per second. All samples were tested in duplicate.
Samples with potential mutations identified by HRM
analysis were sequenced. Each sample was reamplified
with a new reverse sequencing primer to cover the entire
coding region of the exon 4. The sequence of the reverse
primer was 5'-CCCCAAATCTGAATCCCGAGA-3'. PCR
was performed as follows; initial denaturation at 95°C for
15 minutes; 50 cycles of 95°C for 10 seconds, 60°C for 10
seconds, 72°C for 20 seconds with an initial 10 cycles of
touchdown (1°C/cycle starting from 65°C); one cycle of
72°C for 10 minutes. 6 μl of the PCR products were puri-
fied with ExoSapIT (GE Healthcare, Little Chalfont, Eng-
land) followed by sequencing using Big Dye Terminator
v3.1 (Applied Biosystems, Foster City, CA) according to
the manufacturer's protocol. The sequencing products
were ethanol precipitated before running on a 3100
Genetic Analyser (Applied Biosystems). The sequencing
data was analysed using Sequencher 4.6 (Gene Codes
Corporation, Ann Arbor, MI).
Results
HRM analysis on a panel of 219 NSCLC samples identi-
fied four HRM positive samples which displayed aberrant
melting curves compared with wild-type. Their melting
curves were clearly separated from that of wild-type, sug-
gesting that sequence changes were present in those
amplicons (Figure 1). Subsequent sequencing of those
samples revealed an E17K mutation in one sample and a
rare intronic SNP c.47-12G>A (rs17846816) in the
remaining three samples. The E17K mutation was
detected in one of the 14 squamous cell carcinomas, and
was absent in the 141 adenocarcinomas and 39 large cell
carcinomas as well as the 25 samples of unknown or other
histology.
Discussion
High resolution melting (HRM) is a methodology that
can detect sequence changes in amplicons through moni-
toring of the fluorescence of a double stranded DNA bind-
ing dye which dissociates from the DNA as it denatures
with increasing temperature. It is an in-tube method
which can be performed in a fast, simple, and robust man-
ner. If sequence changes, either SNPs and/or mutations,
are present within the amplicon, they cause a difference in
the melting profile compared with the wild-type.
A range of alternative methodologies are available for
screening monomorphic mutations such as the c.49G>A
(E17K). These include PCR-RFLP [11], allele specific com-
petitive blocker polymerase chain reaction [12,13] and
TaqMan "genotyping" [14,15]. Each methodology has its
own particular advantages and disadvantages. The disad-
vantages of these methodologies are that they detect only
specified mutations (competitive blocker, TaqMan) and/
or require post-PCR handling of the product (PCR-RFLP,
competitive blocker) or relatively expensive probes for vis-
ualisation (TaqMan). However, HRM is capable of detect-
ing any sequence changes present within the ampliconBMC Research Notes 2008, 1:14 http://www.biomedcentral.com/1756-0500/1/14
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High resolution melting analysis and sequence traces Figure 1
High resolution melting analysis and sequence traces. Panel A: Normalised plot of AKT1 exon 4. Melting profiles 
of the wild-type control (WT) and four samples (TX25, TX94, TX285, 07M470) are shown. The melting profile of TX25 is sim-
ilar to that of the wild-type control. TX94, TX285 and 07M470 show different melting profiles than the wild-type control. 
Panel B: Difference plot of AKT1 exon 4. Melting profiles of each sample were normalised against the wild-type control 
(WT). TX94, TX285 and 07M470 show distinctively different melting curves. Panel C: Sequencing of the HRM positive 
samples. These identified a rare SNP, IVS3-12G>A, from both TX94 and 07M470. Panel D: Sequencing identifies the 
E17K (c.49G>A) mutation. TX285 was positive for the E17K (c.49G>A) mutation. Sequencing was carried out in both 
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tested, and thus can screen not only the specified muta-
tion but also the whole amplified sequence. Furthermore,
the use of a fluorescent intercalating dye allows HRM to
be performed in-tube, which eliminates post-PCR han-
dling.
In this study, the E17K (c.49G>A) mutation in exon 4 of
the AKT1 gene was screened by HRM with primers gener-
ating a short amplicon of 78 bp suitable for the screening
of formalin-fixed paraffin-embedded samples. By HRM
screening and subsequent sequencing, we found the AKT1
E17K mutation in one of the 219 NSCLC samples. The
tumour sample with the transforming mutation was col-
lected from a female diagnosed with NSCLC at the age of
seventy. The tumour biopsy (2 × 3 mm size) was taken
from the left upper lobe and was histologically confirmed
as squamous cell carcinoma (Figure 2). No mutation was
found in EGFR exons 18 to 21 and KRAS exon 2 in this
sample. More cases need to be studied to determine
whether this mutation is recurrent in squamous cell carci-
nomas.
Association of AKT activation with resistance to chemo-
therapeutic agents has been studied in lung and breast
cancers. AKT1 amplification was shown to be a cause of
cisplatin resistance in lung cancer cells [6]. In another
study, constitutive activation of AKT was found in over
90% of NSCLC cell lines (16/17) and its activation con-
tributed to both PI3K inhibitor (LY294002) and radiation
resistance [16]. In breast cancer cell line studies, AKT acti-
vation markedly increased resistance to microtubule-
directed agents as well as trastuzumab and tamoxifen
treatment [17,18]. Furthermore, the E17K was shown to
alter the sensitivity to an allosteric kinase inhibitor but
not to ATP competitive inhibitors. The finding of this
recurrent AKT1 mutation in various tumours suggests that
AKT may be an attractive therapeutic target for some
patients.
In conclusion, this study shows that the transforming
AKT1 E17K mutation occurs at a very low frequency in
NSCLC. It may be restricted to squamous cell carcinoma
where its frequency is likely to be higher. In addition,
Hematoxylin and eosin stained section of the tumour with an AKT1 E17K mutation Figure 2
Hematoxylin and eosin stained section of the tumour with an AKT1 E17K mutation. A 5 μm tumour section was 
stained with hematoxylin and eosin. The tumour was histologically diagnosed as a squamous cell carcinoma. Two magnifications 
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HRM is an effective screening method for this mutation
due to its low incidence.
Note added in proof
A second study has appeared since this MS was submitted
for review. Malanga et al. examined a panel of 105 NSCLC
by sequencing and observed E17K mutations in two of the
36 squamous cell carcinomas but in no other NSCLC sub-
type [19]. These results and our results considered
together indicate that the E17K mutation is probably lim-
ited to squamous cell carcinomas in NSCLC.
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